<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02390154</url>
  </required_header>
  <id_info>
    <org_study_id>15022</org_study_id>
    <secondary_id>2014-002797-37</secondary_id>
    <nct_id>NCT02390154</nct_id>
  </id_info>
  <brief_title>Roniciclib Mass Balance Study</brief_title>
  <official_title>A Phase I, Single Center, Open-label, Non-randomized, Non-placebo-controlled Study to Investigate the Metabolism, Excretion Pattern, Mass Balance, Safety, Tolerability and Pharmacokinetics of Orally Administered [14C]-Roniciclib (BAY 1000394) in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to investigate the fate of the roniciclib (study drug) in the&#xD;
      body in a so called mass-balance study. This means to investigate how the study drug is&#xD;
      absorbed, distributed, broken down (metabolized) and removed (excreted or eliminated) from&#xD;
      the body.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of Roniciclib in urine as percentage of the dose of total radioactivity.</measure>
    <time_frame>Up to 336 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of Roniciclib in feces as percentage of the dose of total radioactivity.</measure>
    <time_frame>Up to 336 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of Roniciclib in vomit as percentage of the dose of total radioactivity</measure>
    <time_frame>Up to 336 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmaxof roniciclib in plasma</measure>
    <time_frame>up to 336 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-tlast) of roniciclib in plasma</measure>
    <time_frame>up to 336 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of roniciclib in plasma</measure>
    <time_frame>up to 336 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of total radioactivity in whole blood and plasma</measure>
    <time_frame>up to 336 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-tlast) of total radioactivity in whole blood and plasma</measure>
    <time_frame>Up to 336 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of total radioactivity in whole blood and plasma</measure>
    <time_frame>up to 336 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label non-randomized non-controlled mass balance study in Cycle 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label non-randomized non controlled multiple dose study in Cycle 2 and subsequent cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>roniciclib (BAY 1000394)</intervention_name>
    <description>Single dose , 2.5 mg roniciclib spiked with 5.0 MBq of [14C] roniciclib solution</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>roniciclib (BAY 1000394)</intervention_name>
    <description>5 mg roniciclib tablet , Multiple dose, twice a day (bid), on a 3-days on/4-days off regimen in cycles of 21 days</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  - Male or female subjects aged â‰¥18 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2&#xD;
&#xD;
          -  Subjects with advanced, histologically or cytologically confirmed solid tumors,&#xD;
             refractory to any standard therapy, have no standard therapy available, or subjects&#xD;
             must have actively refused any treatment which would be regarded standard, and / or if&#xD;
             in the judgment of the investigator, experimental treatment is clinically and&#xD;
             ethically acceptable&#xD;
&#xD;
          -  Adequate bone marrow, liver, and renal functions as assessed by laboratory&#xD;
             requirements to be conducted within 14 days prior to the first dose of study drug:&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous deep vein thrombosis (within the last 6 months), arterial thrombotic events&#xD;
             (including strokes), or pulmonary embolism&#xD;
&#xD;
          -  History of cardiac disease: congestive heart failure New York Heart Association (NYHA)&#xD;
             class III or IV, angina (within past 6 months prior to study entry), myocardial&#xD;
             infarction, or cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or&#xD;
             digoxin are permitted)&#xD;
&#xD;
          -  Anticancer chemotherapy or immunotherapy within 4 weeks of study entry. Mitomycin C or&#xD;
             nitrosoureas should not be given within 6 weeks of study entry. Accepted exemptions&#xD;
             are bisphosphonates, luteinising hormone releasing hormone (LHRH) agonists for&#xD;
             prostate cancer, and mitotane for adrenal carcinoma.&#xD;
&#xD;
          -  Radiotherapy within 3 weeks prior to the first dose of study drug. Palliative&#xD;
             radiotherapy will be allowed&#xD;
&#xD;
          -  Intake of strong CYP3A4 inhibitors (e.g., boceprevir, clarithromycin, conivaptan,&#xD;
             indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil (withdrawn in&#xD;
             the US), nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir,&#xD;
             telithromycin and voriconazole) and strong CYP3A4 inducers (e.g., carbamazepine,&#xD;
             phenytoin , rifampin and St. John's Wort)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Magyarorszag Kft. Fazis I-es Klin.Farmakol. Vizsgalohely</name>
      <address>
        <city>Budapest</city>
        <zip>1077</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>March 11, 2015</study_first_submitted>
  <study_first_submitted_qc>March 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <last_update_submitted>July 14, 2016</last_update_submitted>
  <last_update_submitted_qc>July 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

